Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer.

Phase II study of FOLFIRI plus Bevacitumab in the treatment of Japanese patients with advanced colorectal cancer. - JACCRO CC-03

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001437

Enrollment

Registered

2008-10-20

Start date

2008-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

(1) Bevaciumab 5mg/Kg i.v. 90min. (2) CPT-11 150mg/m2 i.v. 90min. and Isovorin 200mg/m2 i.v. 90min. (3) 5-FU 400mg/m2 i.v. bolus and 5-FU 2400mg/m2 civ. 46 hours

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Histologically proven colorectal carcinoma. (2)Writtened informed consent. (3) Age 20-74. (4) PS 0-1 (ECOG) (5) Expected 3 months or over survival. (6) Inoperable or reccurent colorectal cancer. (7) No prior chemotherapy. (8) Needs evaluable lesion. (9) Needs adequate hematological function.

Exclusion criteria

Exclusion criteria: (1) Contraindications of using CPT-11, Bevacitumab, 5-FU and Leucovorin (2) Having double or more cancers within 5 yeras. (3).Pregnancy or lactation women, or women with suspected pregnancy or men with willing to get pregnant. (4) Any subject judged by the investigator to be unfit for any reason to participate in the study

Design outcomes

Primary

Measure	Time frame
Progression free survival	—

Secondary

Measure	Time frame
Time to tretment failure Overall survival Response rete Safety	—

Countries

Japan

Contacts

Public ContactToshifusa Nakajima

Japan Clinical Cancer Research Organization Chief Director

jaccro@jaccro.or.jp03-3570-0437

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026